Mesothelioma Cancer Centers
The UNC Lineberger Comprehensive Cancer Center is the only public comprehensive cancer center in North Carolina. The center is located on the UNC Chapel Hill campus and was established in 1975.
The Thoracic Oncology Program at UNC Lineberger Comprehensive Cancer Center treats mesothelioma with a multidisciplinary approach. Experts in thoracic surgery, medical and radiation oncology and pulmonary medicine combine their specializations to provide treatment and care to patients suffering from mesothelioma.
As part of a new patient diagnosis, a team of experts hold a conference to discuss the best method of treatment for a patient based on their diagnosis. Surgery is often a first-line treatment, including pneumonectomy procedures or video-assisted thoracoscopic surgery (VATS) in order to remove the cancerous parts of the lung or the entire lung in some cases. The center is also among the first to utilize CT-based three-dimensional (3D) imaging to plan for radiation treatment. The process can be instrumental in finding the precise location of a tumor for accurate radiation treatment.
Clinical trials are available to patients upon diagnosis if their primary physician thinks the patient may be a good fit and if the patient meets the eligibility criteria for the trial. Their research includes immunology and other emerging therapies. The center offers six support programs through their Comprehensive Cancer Support Program, including mental health services, survivorship, patient and family resources, integrative medicine, support care and wellness.
- Fine needle aspiration
- Transbronchial biopsy
- Thoracoscopic biopsy with CT-guided localization
- Video-assisted thoracoscopic surgery (VATS)
- Commission on Cancer (CoC) accreditation
- National Cancer Institute (NCI) Comprehensive Cancer Center
Mesothelioma Clinical Trials at UNC Lineberger Comprehensive Cancer Center
The following clinical trials are in progress or actively recruiting participants at UNC Lineberger Comprehensive Cancer Center:
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Advanced Malignancies; Metastatic Cancer Last Updated: May 3, 2019 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette